
hpbsurgery.co.nz
Jan 22, 2025, 14:55
Safety and efficacy of PD-1 inhibitor combined with transarterial chemoembolization for intermediate-stage HCC
Journal for ImmunoTherapy of Cancer shared a post on X:
“New JITC article: Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria.”
Authors: Lixing Li, Xin Xu, Wentao Wang, Peiran Huang, Lei Yu, Zhenggang Ren, Jia Fan, Jian Zhou, Lan Zhang, Zheng Wang
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 11:36
Feb 21, 2025, 11:29
Feb 21, 2025, 10:45